Ocean Therapeutics

Alastair McEwan, Chief Executive Officer

A Bachelor of Commerce of the University of Edinburgh, McEwan completed training as a Chartered Accountant under the Scottish Institute in 1979.  He pursued a career through increasingly senior appointments with Doulton Glass Industries, Burroughs Computers and Arthur Young before leading the European expansion of CHC in the early 90s.  He joined the board Inveresk Research in 1996 and took responsibility for its international clinical trials business.  He led the acquisition of ClinTrials in 2001, which tripled the size of the Inveresk Group and positioned it in the top tier of international CROs in preclinical, clinical and laboratory services.  As President, Global Clinical, he had responsibility for all aspects of Inveresk’s international clinical trials business and, as a member of the Group Executive Board, was instrumental to Inveresk’s IPO in 2002 and the subsequent $1.5bn sale to Charles River Laboratories in 2004.  He was Chairman of Cornerstone Therapeutics (NASDAQ: CRTX), during its profitable expansion and reverse take over of Critical Therapeutics, until 2009 when Chiese purchased 51% of the Company.

Brian Dickson M.D., Chief Medical Officer

A physician with 20 yrs experience in the management of pharmaceutical R&D with major pharma (SK&F, Searle, WL/PD), biotech and CROs.  Through board and executive appointments he has had responsibility for over 400 global staff and annual budgets of over $300 million.  These have involved him directly in international clinical development, regulatory affairs and pre-clinical development including toxicology, drug metabolism and molecular pharmacology.  He has led the NDA development, submission teams for seventeen Regulatory applications. These have involved presentations to both CBER and CDER at the FDA as well as the EMEA, HPB, CSM and BGA. His submissions have included new chemical entities, biological, devices, supplemental applications for new indications and new dosage forms.  His NDA applications included cardiovascular (4), oncology (3), anti-infective (2), central nervous system (2), gastroenterology (2), vaccines (2), respiratory (1) and anti-helminthic (1) indications.  He has served on the WHO subcommittee for Nutrition and Anemia; is past Editor-in-Chief, Journal of Pharmaceutical Medicine and is a Member of the Board, American Society of Hypertension.  He was a Board Member of Medeva PLC and Covalent Group Inc (NASDAQ).

John Musante, Chief Commercial Officer

Musante is a twenty-five year pharmaceutical industry veteran of large and small pharmaceutical companies with particular focus on commercial exploitation, market launch and sales for Rx products. He entered the industry in1985 as a field based sales representative for Glaxo. His GSK career includes functional and executive management positions in sales, sales & marketing management, national accounts, business development. He left GSK in the late 90’s to found AcSentient, an ophthalmic company to in license and out license products, leading to a trade sale. He has served as a Senior VP for PDI in licensing activities and later as president and co-founder in Align Pharmaceuticals and Executive VP for Ascend Therapeutics responsible for commercial operations. He has led and directed operations and business development activities for start-ups, participated in fund raising, and executive management with full P&L accountability.